Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Oxytocin PK After IV Administration in Healthy Subjects and Advanced Knee Arthritis Subjects
NCT04429880 · Wake Forest University Health Sciences · PHASE2 · withdrawn · last registry update 2025-08-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was not initiated; no subjects enrolled. A replacement study will be submitted” | – | Registry record, Wake Forest University Health Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OXTR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-02Also stopped (suspended): Icahn School of Medicine at Mount Sinai, 40 IU Intranasal Oxytocin + Placebo (NCT02225600)
- 2026-06-11Results posted on the registry: University of Washington, Oxytocin nasal spray or placebo (NCT05968651)
- 2026-03-27Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Misoprostol (NCT01113229)
- 2026-03-11Results posted on the registry: VA Office of Research and Development, Oxytocin (NCT04228289)
- 2026-02-23Results posted on the registry: University of Florida, Oxytocin (OT) + Placebo (P) (NCT03878589)
- 2026-01-26Also stopped (terminated): Baylor Research Institute, Pitocin (NCT02910115)
- 2026-01-20Results posted on the registry: VA Office of Research and Development, Oxytocin + Placebo (NCT03900754)
- 2026-01-20Also stopped (terminated): VA Office of Research and Development, Oxytocin + Placebo (NCT03900754)
- 2026-01-09Results posted on the registry: The University of Texas Medical Branch, Galveston, Oxytocin (Low dose) + Oxytocin (High dose) (NCT05782816)
- 2025-10-28Results posted on the registry: Wake Forest University Health Sciences, Oxytocin (NCT05929339)
- 2025-10-16Results posted on the registry: Brigham and Women's Hospital, 15-methyl prostaglandin F2α + Methylergonovine Maleate (NCT03584854)
- 2025-09-11Also stopped (terminated): Wake Forest University Health Sciences, Oxytocin (NCT04431206)
- 2025-08-29Results posted on the registry: Wake Forest University Health Sciences, Oxytocin (NCT04431206)
- 2025-08-28Results posted on the registry: Baylor College of Medicine, Oxytocin (NCT05405257)
- 2025-08-28Also stopped (terminated): Baylor College of Medicine, Oxytocin (NCT05405257)
- 2025-08-13Results posted on the registry: University of Arizona, a drug against OXTR (NCT04818112)
- 2025-07-23Results posted on the registry: National Institute on Alcohol Abuse and Alcoholism (NIAAA), Instranasal Oxytocin (NCT03878316)
- 2025-05-25Results posted on the registry: Brown University, intranasal oxytocin, 40 IU, twice a day for 7 days (NCT04051619)
- 2025-05-07Also stopped (terminated): Karolinska Institutet, Oxytocin nasal spray (NCT06199076)
- 2025-04-09Results posted on the registry: Dilafor AB, DF01 + PL1 (NCT04000438)
- 2025-03-27Results posted on the registry: Ferring Pharmaceuticals, FE 992097 + Placebo (NCT01968187)
- 2025-03-26Results posted on the registry: Lane Strathearn, MBBS PhD, Oxytocin + Placebos (NCT02979093)
- 2025-03-26Also stopped (terminated): Lane Strathearn, MBBS PhD, Oxytocin + Placebos (NCT02979093)
- 2025-03-25Results posted on the registry: Oslo University Hospital, Oxytocin + Carbetocin (NCT03899961)
- 2025-03-14Also stopped (terminated): University of Nebraska, Oxytocin Intranasal Spray 8 International Unit (8IU) + Oxytocin intranasal spray 24 International Unit (24IU) (NCT03863288)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision